Emergent BioSolutions (EBS) Tops Q3 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.21, $0.31 better than the analyst estimate of $0.90. Revenue for the quarter came in at $311.8 million versus the consensus estimate of $289.27 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- Gold Royalty Corp. (GROY) Tops Q3 EPS by 1c
- Cedar Fair L.P. (FUN) Misses Q3 EPS by 557c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
